Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million
Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerly JTX-1811), is an antibody drug designed to selectively deplete T regulatory cells in the tumor microenvironment that has entered phase I clinical testing for solid tumors as monotherapy and, in combination with PD-1 inhibitor zimberelimab.
Gilead licensed GS-1811 in 2020 for around USD 800 million, including an USD 85 million upfront payment and a USD 3...
